Abstract 3296: IK-595, a best-in-class MEK-RAF molecular glue, drives broad and potent anti-tumor activity across RAS-MAPK pathway-altered cancers as a monotherapy and in combination

作者
Eric Haines,Rachel Catterall,Victor De Jesus,Daniel Hidalgo,Jill Cavanaugh,Marta Sánchez-Martín,Joseph Manna,Michael Burke,Bin Li,Sarah R. Wessel,Ao Yang,Sergio Santillana,Jeffrey Ecsedy,X. Michelle Zhang,Sabine K. Ruppel
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 3296-3296 被引量:2
标识
DOI:10.1158/1538-7445.am2024-3296
摘要

Abstract Alterations in the RAS/RAF/MEK/ERK pathway are the most common drivers of oncogenesis. Although MEK is a clinically validated cancer target and several MEK inhibitors have been approved by the FDA, their clinical utility has been limited to BRAF V600 mutant cancers and NF1 mutant neurofibromas. We developed the molecular glue, IK-595, a potent inhibitor of the MEK-RAF complex, to overcome the limitations of available MEK inhibitors. IK-595 traps MEK in an inactive complex with all RAF isoforms, as well as mutant forms of BRAF (Class I, II, and III), and blocks RAF-dependent MEK phosphorylation, thereby alleviating CRAF-mediated MEK reactivation that limits the efficacy of approved MEK inhibitors in RAS/RAF-driven tumors. We demonstrate that IK-595 leads to potent and prolonged inhibition of MEK and ERK1/2 phosphorylation in RAS-mutant cancer models. Importantly, IK-595 has a much slower off-rate binding to MEK and retains CRAF longer in an inactive complex with MEK than other MEK/RAF inhibitors, allowing for prolonged target engagement and durable pathway inhibition in RAS/RAF mutant cancer cells. IK-595 exhibits potent single agent activity across a wide range of cancer model indications harboring various RAS/MAPK pathway alterations, including KRAS, NRAS, BRAF and NF1 mutations, and BRAF and CRAF fusions. The benefits of combining IK-595 with inhibitors targeting key resistance mechanisms both within the RAS/MAPK pathway and across parallel survival pathways has also been observed in multiple models. Additionally, IK-595 improved the response of KRAS-driven tumor models to standard of care chemotherapeutic agents, expanding the potential clinical opportunity for IK-595. Key to the design of IK-595 is its PK profile that enables transient high plasma drug exposure and flexible dosing schedules. Intermittent dosing of IK-595 every other day (QOD) or every three days (Q3D) in KRAS-mutant mouse tumor models shows similar efficacy and improved tolerability compared to daily dosing (QD), affording a larger therapeutic window. Preclinical pharmacology studies provide clear guidance to the clinical development plan of IK-595, where flexible dosing schedules, multiple expansion cohorts in RAS/RAF altered patient populations, and combination therapies with mediators of resistance will be explored. IK-595 is a novel MEK-RAF molecular glue that prolongs pathway inhibition, minimizing the potential for resistance, while providing an optimal therapeutic window for patients with RAS/RAF-driven cancer. Citation Format: Eric Haines, Rachel Catterall, Victor De Jesus, Daniel Hidalgo, Jill Cavanaugh, Marta Sanchez-Martin, Joseph D. Manna, Michael Burke, Bin Li, Sarah R. Wessel, Ao Yang, Sergio Santillana, Jeffrey Ecsedy, X. Michelle Zhang, Sabine K. Ruppel. IK-595, a best-in-class MEK-RAF molecular glue, drives broad and potent anti-tumor activity across RAS-MAPK pathway-altered cancers as a monotherapy and in combination [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3296.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
充电宝的应助被zqy采纳,获得10
刚刚
SciGPT的应助被gqz采纳,获得10
刚刚
神勇秋蝶发布了新的文献求助10
刚刚
1秒前
fx发布了新的文献求助10
1秒前
1秒前
1秒前
时思发布了新的文献求助10
1秒前
Ava的应助被rururu采纳,获得10
1秒前
NexusExplorer的应助被彩色鸿涛采纳,获得10
1秒前
3秒前
3秒前
孙浩文发布了新的文献求助10
3秒前
QQ发布了新的文献求助10
4秒前
Huaaaaay完成签到,获得积分10
4秒前
4秒前
勒言完成签到,获得积分10
4秒前
张张的应助被含糊的静芙采纳,获得10
5秒前
hazeoO发布了新的文献求助10
6秒前
6秒前
麦粑块发布了新的文献求助10
6秒前
岳鑫发布了新的文献求助30
6秒前
水沐菁华发布了新的文献求助10
8秒前
诚心的琦完成签到,获得积分10
8秒前
8秒前
俭朴南风发布了新的文献求助10
8秒前
9秒前
9秒前
gsokok完成签到,获得积分10
11秒前
盒子发布了新的文献求助10
11秒前
王亚娟发布了新的文献求助10
12秒前
JamesPei的应助被lxlx111采纳,获得10
12秒前
科研通AI6.4的应助被lanchuan采纳,获得10
12秒前
13秒前
CodeCraft的应助被时思采纳,获得10
13秒前
宇明完成签到,获得积分10
13秒前
Huaaaaay发布了新的文献求助10
14秒前
十四完成签到,获得积分10
14秒前
14秒前
Paranoieam完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239